What happened with IDYA today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
IDEAYA Biosciences is a clinical-stage drug developer with no medicines approved for sale and no product-sales revenue. It develops cancer treatments that use molecular features of tumors to guide patient selection. Its pipeline includes darovasertib for uveal melanoma, a cancer of the eye.
Servier is its main revenue partner. In exchange for exclusive rights to develop and sell darovasertib outside the United States, Servier paid IDEAYA an upfront license fee. The companies share development costs, and IDEAYA can receive further payments when development, regulatory or commercial milestones are met, plus royalties if sales begin. Servier handles regulatory and commercial activities in those markets; IDEAYA retains U.S. rights. The overseas business therefore depends heavily on Servier’s execution, while product revenue requires successful development and regulatory approval. IDEAYA has primarily funded its operations through share sales and collaboration and licensing payments, rather than medicine sales.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
IDEAYA hinges on clinical success, especially darovasertib, and on privately held Servier, its partner for rights outside the U.S., upfront payments, potential milestones, cost sharing and royalties.
Immunocore gives IDEAYA’s darovasertib a clinical and sales benchmark through KIMMTRAK, which it sells for adults with HLA-A*02:01-positive unresectable or metastatic uveal melanoma. Watch KIMMTRAK adoption, while keeping that patient group distinct from IDEAYA’s first-line HLA-A*02:01-negative metastatic trial.
Tango Therapeutics challenges IDEAYA’s MTAP-pathway drugs, including IDE397 and its competing PRMT5 candidate, with medicines designed for MTAP-deleted cancers. Its vopimetostat and TNG456 trial results are the concrete comparison to watch; neither company’s competing PRMT5 approach has an approved product.
Delcath competes for treatment use in the metastatic uveal melanoma market targeted by IDEAYA’s darovasertib combination, selling HEPZATO KIT in the U.S. for certain adults with unresectable liver metastases. Its treatment use shows uptake of a liver-directed option that delivers melphalan chemotherapy through a dedicated delivery and blood-filtering system.
Replimune’s RP2 could compete with IDEAYA’s darovasertib combination for metastatic uveal melanoma patients, although Replimune has no approved products or product-sales revenue. Watch its potentially registration-enabling trial of RP2 plus nivolumab in adults who have not received immune-checkpoint inhibitors.
IDEAYA relies on Pfizer to supply crizotinib for trials combining it with darovasertib, its lead uveal melanoma candidate; Pfizer’s main business is selling medicines. The relevant news is this drug-supply collaboration and the combination’s trial progress, rather than Pfizer’s overall sales.
IDEAYA depends on Novartis’s exclusive license for the intellectual property behind darovasertib, while Novartis also develops the competing uveal melanoma treatment DYP688. Watch DYP688’s clinical progress alongside the license supporting IDEAYA’s ability to develop and sell darovasertib.
Eikon Therapeutics’ EIK1005 competes with IDEAYA’s IDE275: both are clinical-stage drugs that inhibit the WRN helicase enzyme. EIK1005’s trial results are the relevant comparison for IDE275; Eikon has no approved products or product-sales revenue.
Zai Lab’s ZL-1310 directly competes with IDEAYA’s IDE849 in small-cell lung cancer; both attach a drug to an antibody targeting DLL3. Watch ZL-1310’s Phase 3 trial in relapsed disease, while noting that IDEAYA’s IDE849 rights exclude Greater China.
Amgen’s marketed Imdelltra sets a competing treatment standard for IDEAYA’s IDE849: both target DLL3, but Imdelltra brings T cells to the target while IDE849 delivers an antibody-linked drug. Watch Imdelltra’s use as an established treatment, rather than Amgen’s broader medicine sales to wholesalers and healthcare providers.
Immatics’ cell therapy anzu-cel/IMA203 offers a competing treatment approach for the uveal melanoma targeted by IDEAYA’s darovasertib. Watch that program’s clinical progress; its cell-therapy approach differs from IDEAYA’s drug program.
IDEAYA depends on Gilead to supply Trodelvy for combination studies with IDE397 in MTAP-deleted urothelial cancer and non-small cell lung cancer. Watch results in those patient groups; each company keeps full commercial rights to its own drug.
Novartis AG earningsNVS
Novartis’s report can show whether DYP688 is advancing clinically, adding a competing uveal-melanoma program alongside the licensed intellectual property IDEAYA relies on for darovasertib.
Look for disclosed clinical progress on DYP688 and how it relates to the disease darovasertib targets. Progress would show another potential treatment approach advancing for uveal melanoma patients; limited progress would mean that competitive signal has less clinical backing. Novartis’s report does not establish any change in IDEAYA’s license rights.
Tango Therapeutics, Inc. earningsTNGX
Tango Therapeutics’s report can show whether its drugs for MTAP-deleted cancers are advancing, as they compete with IDEAYA’s IDE397 for the same patient groups.
Look for trial progress on Tango’s vopimetostat and TNG456. Clinical progress would make competition for the same MTAP-deleted cancer groups more concrete for IDE397; limited progress would leave Tango’s candidates with less clinical support, but would not substitute for IDE397’s own trial results. Neither company has an approved competing product.
Zai Lab Limited earningsZLAB
Zai Lab’s report can show whether its DLL3-targeting antibody-drug conjugate ZL-1310 is advancing in Phase 3, a close comparison for IDEAYA’s IDE849 in small-cell lung cancer.
Track ZL-1310’s Phase 3 trial in relapsed disease and compare its progress with IDE849’s clinical stage and approach. Advancement would show a similar DLL3-targeting antibody-drug conjugate moving through a more consequential test; setbacks would weaken the clinical case for this direct competitor. Zai Lab’s program cannot establish IDE849’s efficacy, and IDE849 rights exclude Greater China.
Immunocore Holdings plc earningsIMCR
Immunocore’s report can show KIMMTRAK use among a specific uveal-melanoma patient group, offering a treatment-adoption reference for IDEAYA’s darovasertib in a different group.
Look for KIMMTRAK sales or use, keeping its population distinct: adults with HLA-A*02:01-positive unresectable or metastatic uveal melanoma. IDEAYA’s described first-line metastatic trial is in HLA-A*02:01-negative patients. Rising use would show adoption of an approved treatment in its defined group; weaker use would show less adoption there. The populations differ, so KIMMTRAK sales do not directly predict demand for darovasertib.
IDEAYA Biosciences, Inc. earningsThis company
IDEAYA has no approved products to sell, so its report shows how quickly it is spending on clinical development and how collaboration revenue affects that cash use.
Read research and development and other operating costs alongside operating cash use and clinical-program progress. Slower spending and cash use with programs advancing would show that funding is supporting development without a faster drain; faster cash use with limited progress would mean the pipeline is consuming funds more quickly, leaving future development more dependent on available cash and collaborators. Read collaboration revenue in light of its source and recognition timing: a quarterly increase does not mean a drug is approved or being sold.
